Key facts

Financial results (Full-year 2019)

Product Sales

Change at constant exchange rates

Core Earnings per Share

Change at constant exchange rates



SEC filings

SEC filings are those documents that we are required to file by virtue of our listing on the New York Stock Exchange. They contain mainly financial information.

These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:

Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA


Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

167

projects in our pipeline

7

new molecular entities in our late-stage pipeline

1

new molecular entity approval in the last quarter



Contact us

Investor enquiries

Main Contacts

Thomas Kudsk Larsen

Henry Wheeler

Oncology

Josie Afolabi

BioPharmaceuticals (Respiratory & Immunology)

Craig Marks

Finance, fixed income

Christer Gruvris

BioPharmaceuticals (CV, Metabolism)

Tom Waldron

Other medicines

Jennifer Kretzmann

Corporate access, retail investors

Nick Stone

BioPharmaceuticals (Renal), ESG

US general enquiries


  • Annual reports

    Our Annual Report provides a wide range of information about our global business.


  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development